|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Division of Neurochemistry, New England Primate Research Center, Harvard Medical School, Southborough, Massachusetts
Recently identified trace amine receptors are potential direct targets for drugs of abuse, including amphetamine and 3,4-methylenedioxymethamphetamine (MDMA). We cloned full-length rhesus monkey trace amine receptor 1 (rhTA1) that was 96% homologous to human TA1. The trace amines tyramine and
-phenylethylamine (PEA) and the monoamine transporter substrates (±)-amphetamine and (±)-MDMA stimulated cAMP accumulation in rhTA1-expressing cell lines, as measured by a cAMP response element-luciferase assay. Cocaine did not stimulate cAMP accumulation in rhTA1 cells, but it blocked [3H]PEA transport mediated by the dopamine transporter. Cotransfection with the human dopamine transporter enhanced PEA-, amphetamine-, and MDMA-mediated rhTA1 receptor activation, but it diminished tyramine activation of rhTA1. Because TA1 (EGFP-rhTA1 chimera) was largely intracellular, conceivably the dopamine transporter can facilitate access of specific agonists to intracellular TA1. rhTA1 mRNA expression was detected in rhesus monkey substantia nigra, implying that TA1 may be colocalized with the dopamine transporter in dopamine neurons. In summary, primate TA1 receptors are direct targets of trace amines, amphetamine, and MDMA. These receptors could also be indirect targets of amphetamine, MDMA, and cocaine through modification of monoamine transporter function. Conceivably, rhTA1 receptors may be located on pre- or postsynaptic membranes. Interference with the carrier function of monoamine transporters with a consequent rise of extracellular levels of trace amines could activate these receptors. The cloning of a highly homologous TA1 from rhesus monkey and demonstration that rhTA1 receptors are activated by drugs of abuse, indicate that nonhuman primates may serve to model physiological and pharmacological TA1-mediated responses in humans.
Address correspondence to: Dr. Bertha K. Madras, Department of Psychiatry, New England Primate Research Center, Harvard Medical School, One Pine Hill Dr., Southborough, MA 01772. E-mail: bertha_madras{at}hms.harvard.edu
This article has been cited by other articles:
![]() |
T. D. Sotnikova, M. G. Caron, and R. R. Gainetdinov Trace Amine-Associated Receptors as Emerging Therapeutic Targets Mol. Pharmacol., August 1, 2009; 76(2): 229 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie and G. M. Miller A Receptor Mechanism for Methamphetamine Action in Dopamine Transporter Regulation in Brain J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 316 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Maguire, W. A. E. Parker, S. M. Foord, T. I. Bonner, R. R. Neubig, and A. P. Davenport International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature Pharmacol. Rev., March 1, 2009; 61(1): 1 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Barak, A. Salahpour, X. Zhang, B. Masri, T. D. Sotnikova, A. J. Ramsey, J. D. Violin, R. J. Lefkowitz, M. G. Caron, and R. R. Gainetdinov Pharmacological Characterization of Membrane-Expressed Human Trace Amine-Associated Receptor 1 (TAAR1) by a Bioluminescence Resonance Energy Transfer cAMP Biosensor Mol. Pharmacol., September 1, 2008; 74(3): 585 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie and G. M. Miller {beta}-Phenylethylamine Alters Monoamine Transporter Function via Trace Amine-Associated Receptor 1: Implication for Modulatory Roles of Trace Amines in Brain J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 617 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie, S. V. Westmoreland, and G. M. Miller Modulation of Monoamine Transporters by Common Biogenic Amines via Trace Amine-Associated Receptor 1 and Monoamine Autoreceptors in Human Embryonic Kidney 293 Cells and Brain Synaptosomes J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 629 - 640. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D Verrico, L. Lynch, M. A Fahey, A.-K. Fryer, G. M Miller, and B. K Madras MDMA-induced impairment in primates: antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor J Psychopharmacol, March 1, 2008; 22(2): 187 - 202. [Abstract] [PDF] |
||||
![]() |
E. A. Reese, J. R. Bunzow, S. Arttamangkul, M. S. Sonders, and D. K. Grandy Trace Amine-Associated Receptor 1 Displays Species-Dependent Stereoselectivity for Isomers of Methamphetamine, Amphetamine, and Para-Hydroxyamphetamine J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 178 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie, S. V. Westmoreland, M. E. Bahn, G.-L. Chen, H. Yang, E. J. Vallender, W.-D. Yao, B. K. Madras, and G. M. Miller Rhesus Monkey Trace Amine-Associated Receptor 1 Signaling: Enhancement by Monoamine Transporters and Attenuation by the D2 Autoreceptor in Vitro J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 116 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie and G. M. Miller Trace Amine-Associated Receptor 1 Is a Modulator of the Dopamine Transporter J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 128 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Madras, Z. Xie, Z. Lin, A. Jassen, H. Panas, L. Lynch, R. Johnson, E. Livni, T. J. Spencer, A. A. Bonab, et al. Modafinil Occupies Dopamine and Norepinephrine Transporters in Vivo and Modulates the Transporters and Trace Amine Activity in Vitro J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 561 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Navarro, B. P. Gilmour, and A. H. Lewin A Rapid Functional Assay for the Human Trace Amine-Associated Receptor 1 Based on the Mobilization of Internal Calcium J Biomol Screen, September 1, 2006; 11(6): 688 - 693. [Abstract] [PDF] |
||||